CSI Announces the Introduction of MPT-IV, a Wireless, Portable Monitor for Vital Signs and IV Therapy.

Business Editors, Health Writers

MILWAUKEE--(BUSINESS WIRE)--Nov. 7, 2000

CRITICARE SYSTEMS, INC. (NASDAQ-NMS: CXIM) today announced the introduction of MPT-IV, a wireless, pole mounted, three-parameter vital signs monitor, able to attach to a communications-ready IV pump. This system permits mobile communication of a patient's vital signs as well as all critical fluid infusion parameters, including alarm thresholds.

The portable MPT-IV is approximately half the size of the average IV pump and is mounted above the pump on the same IV pole. As the patient moves about taking the rollstand and pump, the monitor goes along and wirelessly transmits real time patient data and IV pump information to the central station. This keeps the patient in constant communication, stationary or mobile.

The system requires no interaction by the clinician-it automatically recognizes the make and model pump it is attached to. The library of software currently embedded in the MPT-IV addresses communication-ready IV pumps from major manufacturers. It can also be used as a stand alone wireless portable monitor without the IV connection for maximum flexibility. This system is proprietary to CSI with patents applied for earlier this year.

CSI president and CEO, Emil Soika, stated, "The MPT-IV wireless monitor represents a highly versatile, cost effective clinical tool. It is designed to augment patient safety and clinical confidence by providing uninterrupted communication of vital signs and fluid infusion data under mobile as well as stationary conditions."

Criticare Systems, Inc. (www.csiusa.com) designs, manufactures, and markets cost-effective patient monitoring systems and noninvasive sensors for a wide range of hospitals and alternate health care environments throughout the world.

This press release contains forward-looking statements. Such statements refer to the company's beliefs and expectations. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described. Such uncertainties include, but are not limited to, the timely completion of new products, regulatory approvals for new products, the risk of new and better technologies, risks relating to international markets, as well as general conditions and competition in the company's markets. Other risks are set forth in CSI's reports and documents filed from time to time with the Securities and Exchange Commission.